Prana has today announced that is has received a A$3.02 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
AGM Presentation 2017
Prana Biotechnology invites investors unable to attend the Annual General Meeting to participate via teleconference.
Prana has announced that it has filed its Annual Report on Form 20-F
PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture
Scientific Journal Acta Neuropathologica publishes pre-clinical data
David Stamler, M.D., has joined Prana Biotechnology (ASX PBT, NASDAQ PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco.
Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.